COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID
Journal
Multiple Sclerosis and Related Disorders
ISSN
2211-0348
Date Issued
2020
Author(s)
Fiorella Celsi Young
Galleguillos Lorna
Type
Resource Types::text::journal::journal article
Subjects
alemtuzumab
;
coronavirus 2019
;
immunity
;
multiple sclerosis
;
reinfection
;
alemtuzumab
;
covid-19
;
female
;
humans
;
immunity
;
multiple sclerosis
;
sars-cov-2
;
young adult
;
alemtuzumab
;
antidepressant agent
;
immunoglobulin g
;
levdropropizine
;
methylprednisolone
;
paracetamol
;
steroid
;
alemtuzumab
;
adult
;
ataxia
;
case report
;
clinical article
;
coronavirus disease 2019
;
coughing
;
depression
;
diplopia
;
female
;
fever
;
human
;
immune response
;
immunoaffinity chromatography
;
letter
;
lymphocytopenia
;
multiple cycle treatment
;
multiple sclerosis
;
myalgia
;
nose smear
;
nuclear magnetic resonance imaging
;
polymerase chain reaction
;
quarantine
;
sore throat
;
vertigo
;
young adult
;
complication
;
drug effect
;
immunity
;
immunology
;
multiple sclerosis
;
pathogenicity
;
virology